Characteristics of patients with stage T2 or T3 gallbladder cancer who underwent surgical resection in Ontario, Jan. 1, 2002, to Mar. 31, 2012
| Characteristic | T2; no. (%) of patients* | T3; no. (%) of patients* | ||||
|---|---|---|---|---|---|---|
| All n = 232 | Simple n = 176 | Extended n = 56 | All n = 138 | Simple n = 87 | Extended n = 51 | |
| Age category, yr | ||||||
| 18–60 | 62 (26.7) | 41 (23.3) | 21 (37.5) | 35 (25.4) | 15–20 (17.2–23.0) | 15–20 (29.4–39.2) |
| 61–80 | 131 (56.5) | 95–100 (54.0–56.8) | 30–35 (53.6–62.5) | 83 (60.1) | 51 (58.6) | 32 (62.7) |
| ≥ 81 | 39 (16.8) | 35–40 (19.9–22.7) | < 6 (0.0–8.9)† | 20 (14.5) | 15–20 (17.2–23.0) | < 6 (0.0–9.8)† |
| Age, mean ± SD, yr | 68.3 ± 11.0 | 69.8 ± 11.2 | 63.4 ± 10.8 | 68.7 ± 11 | 70.0 ± 11.6 | 66.3 ± 9.9 |
| Sex | ||||||
| Female | 156 (67.2) | 116 (65.9) | 40 (71.4) | 99 (71.7) | 59 (67.8) | 40 (78.4) |
| Male | 75 (32.3) | 60 (34.1) | 15 (26.8) | 39 (28.3) | 28 (32.2) | 11 (21.6) |
| Missing | 1 (0.4) | 0 (0.0) | 1 (1.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Socioeconomic status | ||||||
| Q1 (lowest) | 48 (20.7) | 41 (23.3) | 7 (12.5) | 23 (16.7) | 15–20 (17.2–23.0) | 5–10 (9.8–19.6) |
| Q2 | 45 (19.4) | 37 (21.0) | 8 (14.3) | 31 (22.5) | 20 (23.0) | 11 (21.6) |
| Q3 | 47 (20.2) | 32 (18.2) | 15 (26.8) | 28 (20.3) | 18 (20.7) | 10 (19.6) |
| Q4 | 32 (13.8) | 22 (12.5) | 10 (17.8) | 20 (14.5) | 11 (12.6) | 9 (17.6) |
| Q5 (highest) | 37 (15.9) | 28 (15.9) | 9 (16.1) | 17 (12.3) | 10–15 (11.5–17.2) | < 6 (0.0–9.8)† |
| Missing | 23 (9.9) | 16 (9.1) | 7 (12.5) | 19 (13.8) | 11 (12.6) | 8 (15.7) |
| Surgery | ||||||
| Simple | 176 (75.6) | 176 (100.0) | — | 87 (63.0) | 87 (100.0) | — |
| Extended | 56 (24.1) | — | 56 (100.0) | 51 (37.0) | — | 51 (100.0) |
| Upfront | 23 (9.9) | — | 23 (41.1) | 36 (26.1) | — | 36 (70.6) |
| Delayed | 33 (14.2) | — | 33 (58.9) | 15 (10.9) | — | 15 (29.4) |
| Adjuvant treatment | 29 (12.5) | 12 (6.8) | 17 (30.4) | 19 (13.8) | 10 (11.5) | 9 (17.6) |
| Grade | ||||||
| Well | 45 (19.4) | 33 (18.8) | 12 (21.4) | 21 (15.2) | 10 (11.5) | 11 (21.6) |
| Moderate | 106 (45.7) | 82 (46.6) | 24 (42.8) | 53 (38.4) | 35 (40.2) | 18 (35.3) |
| Poor | 67 (28.9) | 48 (27.3) | 19 (33.9) | 56 (40.6) | 38 (43.7) | 18 (35.3) |
| Missing | 14 (6.0) | 13 (7.4) | 1 (1.8) | 8 (5.8) | 4 (4.6) | 4 (7.8) |
| Perineural invasion | ||||||
| Absent | 72 (31.0) | 46 (26.1) | 26 (46.4) | 23 (16.7) | 13 (14.9) | 10 (19.6) |
| Present | 81 (34.9) | 59 (33.5) | 22 (39.3) | 60 (43.5) | 35 (40.2) | 25 (49.0) |
| Missing | 79 (34.0) | 71 (40.3) | 8 (14.3) | 55 (39.8) | 39 (44.8) | 16 (31.4) |
| Lymphovascular invasion | ||||||
| Present | 95 (40.9) | 72 (40.9) | 23 (41.1) | 39 (28.3) | 27 (31.0) | 8 (15.7) |
| Absent | 89 (38.4) | 64 (36.4) | 25 (44.6) | 62 (44.9) | 35 (40.2) | 31 (60.8) |
| Missing | 48 (20.7) | 40 (22.7) | 8 (14.3) | 37 (26.8) | 25 (28.7) | 12 (23.5) |
| Margin status | ||||||
| Negative | 142 (61.2) | 89 (50.6) | 53 (94.6) | 59 (42.8) | 22 (25.3) | 37 (72.5) |
| Any positive | 43 (18.5) | 40–45 (22.7–25.6) | < 6 (0.0–8.9)† | 69 (50.0) | 55 (63.2) | 14 (27.4) |
| Missing | 46 (19.8) | 40–45 (22.7–25.6) | < 6 (0.0–8.9)† | 10 (7.2) | 10 (11.5) | 0 (0.0) |
| Lymph node status | ||||||
| Negative | 50 (21.6) | 29 (16.5) | 21 (37.5) | 27 (19.6) | < 6 (0.0–5.7)† | 20–25 (39.2–49.0) |
| Positive | 63 (27.2) | 30–35 (17.0–19.9) | 30–35 (53.4–62.5) | 46 (33.3) | 23 (26.4) | 23 (45.1) |
| Missing | 119 (51.3) | 115–120 (65.3–68.2) | < 6 (0.0–8.9)† | 65 (47.1) | 55–60 (63.2–69.0) | < 6 (0.0–9.8)† |
| No. of nodes | ||||||
| 0 | 124 (53.4) | 120–124 (68.2–70.4) | < 6 (0.0–8.9)† | 67 (48.6) | 60 (69.0) | 7 (13.7) |
| 1 | 51 (22.0) | 40 (22.7) | 11 (19.6) | 35 (25.4) | 23 (26.4) | 12 (23.5) |
| 2 | 21 (9.0) | 15 (8.5) | 6 (10.7) | 12 (8.7) | < 6 (0.0–5.7)† | 5–10 (9.8–19.6) |
| ≥ 3 | 36 (15.5) | < 6 (0.0–2.8)† | 35–40 (60.2–71.4) | 24 (17.4) | < 6 (0.0–5.7)† | 20–25 (39.2–49.0) |
| Mean ± SD | 1.31 ± 2.3 | 0.4 ± 0.7 | 4.1 ± 3.2 | 1.6 ± 2.8 | 0.3 ± 0.6 | 3.7 ± 3.8 |